Arrowhead Pharmaceuticals Hits New 52-Week High of $44.80

Arrowhead Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 44.80 on November 24, 2025. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 3,756 million.
Over the past year, Arrowhead Pharmaceuticals has demonstrated impressive growth, with a performance increase of 80.58%, significantly outpacing the S&P 500's 11.0% gain during the same period. Despite its recent success, the company remains in a loss-making position, reflected in its price-to-earnings ratio, which is not applicable.

The stock's price-to-book ratio stands at 7.19, indicating a premium valuation relative to its book value. Additionally, Arrowhead Pharmaceuticals has a debt-to-equity ratio of -0.56, suggesting a unique financial structure. However, the company does not offer a dividend yield, aligning with its focus on growth and reinvestment in its operations. This recent high marks a notable point in the company's trajectory within the competitive biotechnology landscape.